Publicaciones en colaboración con investigadores/as de Hospital Universitario Reina Sofia (27)

2023

  1. Clinical Profiles and Patterns of Kidney Disease Progression in C3 Glomerulopathy

    Kidney360, Vol. 4, Núm. 5, pp. 659-672

  2. Consensus document of the Spanish Group for the Study of the Glomerular Diseases (GLOSEN) for the diagnosis and treatment of lupus nephritis

    Nefrologia, Vol. 43, Núm. 1, pp. 6-47

  3. Effect of Immunosuppressive Treatments on Kidney Outcomes After Gross Hematuria-Related Acute Kidney Injury in Older Patients With IgA Nephropathy

    Kidney International Reports, Vol. 8, Núm. 8, pp. 1596-1604

  4. Thrombotic microangiopathy in patients with malignant hypertension

    Nephrology Dialysis Transplantation, Vol. 38, Núm. 5, pp. 1217-1226

2022

  1. Development and validation of a nomogram to predict kidney survival at baseline in patients with C3 glomerulopathy

    Clinical Kidney Journal, Vol. 15, Núm. 9, pp. 1737-1746

  2. Longitudinal change in proteinuria and kidney outcomes in C3 glomerulopathy

    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, Vol. 37, Núm. 7, pp. 1270-1280

2021

  1. The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy

    Kidney International, Vol. 99, Núm. 4, pp. 986-998

2020

  1. Mycophenolate mofetil in c3 glomerulopathy and pathogenic drivers of the disease

    Clinical Journal of the American Society of Nephrology, Vol. 15, Núm. 9, pp. 1287-1298

2019

  1. Complement activation and thrombotic microangiopathies

    Clinical Journal of the American Society of Nephrology, Vol. 14, Núm. 12, pp. 1719-1732

  2. IgA nephropathy in elderly patients

    Clinical Journal of the American Society of Nephrology, Vol. 14, Núm. 8, pp. 1183-1192

  3. Returning to haemodialysis after kidney allograft failure: A survival study with propensity score matching

    Nephrology Dialysis Transplantation, Vol. 34, Núm. 4, pp. 667-672

  4. Severe and malignant hypertension are common in primary atypical hemolytic uremic syndrome

    Kidney International, Vol. 96, Núm. 4, pp. 995-1004

2018

  1. A retrospective study of pregnancy-associated atypical hemolytic uremic syndrome

    Kidney International, Vol. 93, Núm. 2, pp. 450-459

  2. Podocytes are new cellular targets of haemoglobin-mediated renal damage

    Journal of Pathology, Vol. 244, Núm. 3, pp. 296-310

  3. Proton Pump Inhibitor Usage and the Risk of Mortality in Hemodialysis Patients

    Kidney International Reports, Vol. 3, Núm. 2, pp. 374-384

2017

  1. Eculizumab in secondary atypical haemolytic uraemic syndrome

    Nephrology Dialysis Transplantation, Vol. 32, Núm. 3, pp. 466-474

  2. Elevated factor H–related protein 1 and factor H pathogenic variants decrease complement regulation in IgA nephropathy

    Kidney International, Vol. 92, Núm. 4, pp. 953-963

  3. The Combination of Beta Blockers and Renin-Angiotensin System Blockers Improves Survival in Incident Hemodialysis Patients: A Propensity-Matched Study

    Journal of Computational Design and Engineering, Vol. 4, Núm. 3, pp. 665-675

2016

  1. Altered underlying renal tubular function in patients with chronic hepatitis B receiving nucleos(t)ide analogs in a real-world setting the MENTE study

    Journal of Clinical Gastroenterology, Vol. 50, Núm. 9, pp. 779-789

2015

  1. An update for atypical haemolytic uraemic syndrome: Diagnosis and treatment. A consensus document

    Nefrologia